Payment overview · 2025
General Payments
$976.90
44 reported records · 19 companies
Healthcare provider profile · identity verified
Mark D Lafuria, MD
Allopathic & Osteopathic Physicians|Internal Medicine · LAKE CHARLES, LA · NPI 1427181908
Verified facts
What the public records show
CMS Open Payments records show Mark D Lafuria, MD received $976.90 in general payments during 2025 across 44 reported records.
Amgen Inc. accounted for 21.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 22 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Farxiga, Jardiance, Mounjaro, Ozempic, Rexulti, Trintellix.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 86 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LUMIGAN as an associated drug or biological on 25016 records involving 7645 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Lumigan by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 62 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Vraylar by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 223 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 215 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 64 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 215 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 85 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Trulicity by this doctor in 2024.
Lundbeck LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 71829 records involving 25812 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Rexulti by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 70 claims for Entresto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 33 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Rybelsus by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Tresiba as an associated drug or biological on 415 records involving 264 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Tresiba by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Rexulti by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 750 claims for Eliquis by this doctor in 2024.
Takeda Pharmaceuticals U.S.A., Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRINTELLIX as an associated drug or biological on 37075 records involving 14402 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Trintellix by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Amgen Inc. | Unresolved — no canonical attribution shown | $212.42 | 21.7% | 10 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $209.70 | 21.5% | 5 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $95.51 | 9.8% | 4 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $62.92 | 6.4% | 3 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $58.33 | 6.0% | 3 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $52.88 | 5.4% | 3 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $37.88 | 3.9% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $33.06 | 3.4% | 2 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $32.89 | 3.4% | 2 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $23.27 | 2.4% | 1 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $20.77 | 2.1% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $20.42 | 2.1% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $18.16 | 1.9% | 1 | 2025 |
| Currax Pharmaceuticals LLC | Unresolved — no canonical attribution shown | $18.00 | 1.8% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $18.00 | 1.8% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $17.70 | 1.8% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $15.79 | 1.6% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $14.86 | 1.5% | 1 | 2025 |
| Biogen, Inc. | Unresolved — no canonical attribution shown | $14.34 | 1.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $976.90 | 44 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $212.42 | 10 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $209.70 | 5 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $95.51 | 4 | 2025 |
Source payment records
|
|||||
| TRINTELLIX Normalized: trintellix |
Drug | Takeda Pharmaceuticals U.S.A., Inc. | $62.92 | 3 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $48.37 | 2 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $41.27 | 2 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $39.50 | 2 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $37.88 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $36.92 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $36.92 | 2 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $33.66 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $33.06 | 2 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $32.89 | 2 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $20.77 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $20.42 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $20.42 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $18.83 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $18.16 | 1 | 2025 |
Source payment records
|
|||||
| CONTRAVE Normalized: contrave |
Drug | Currax Pharmaceuticals LLC | $18.00 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $15.79 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $14.86 | 1 | 2025 |
Source payment records
|
|||||
| SKYCLARYS Normalized: skyclarys |
Drug | Biogen, Inc. | $14.34 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 750 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 223 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 215 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 85 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 33 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 25 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRINTELLIX trintellix |
2025 | Trintellix | 2024 | 30 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
86 | 20 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LUMIGAN open payments reported associated product |
CMS Open Payments — General Payments 25016 supporting records · 7645 recipient NPIs · example record 1201352548 |
Lumigan · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
62 | 16 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
223 | 27 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
215 | 22 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
64 | 11 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
215 | 22 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
85 | 18 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Lundbeck LLC Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 71829 supporting records · 25812 recipient NPIs · example record 1251759986 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
70 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
33 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Tresiba open payments reported associated product |
CMS Open Payments — General Payments 415 supporting records · 264 recipient NPIs · example record 1188130328 |
Tresiba · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
750 | 72 |
| Takeda Pharmaceuticals U.S.A., Inc. Exact reporting entity; no affiliate inference |
2025 | TRINTELLIX open payments reported associated product |
CMS Open Payments — General Payments 37075 supporting records · 14402 recipient NPIs · example record 1223616266 |
Trintellix · 2024 Exact normalized brand match · 1 Part D row |
30 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1857 | 302 |
| Amlodipine Besylate | Amlodipine Besylate | 971 | 200 |
| Levothyroxine Sodium | Levothyroxine Sodium | 930 | 155 |
| Pantoprazole Sodium | Pantoprazole Sodium | 839 | 154 |
| Eliquis | Apixaban | 750 | 72 |
| Losartan Potassium | Losartan Potassium | 655 | 129 |
| Gabapentin | Gabapentin | 577 | 100 |
| Metoprolol Tartrate | Metoprolol Tartrate | 552 | 83 |
| Furosemide | Furosemide | 542 | 110 |
| Mirtazapine | Mirtazapine | 533 | 86 |
| Clopidogrel | Clopidogrel Bisulfate | 505 | 74 |
| Trazodone Hcl | Trazodone Hcl | 499 | 91 |
| Tamsulosin Hcl | Tamsulosin Hcl | 486 | 85 |
| Duloxetine Hcl | Duloxetine Hcl | 485 | 78 |
| Potassium Chloride | Potassium Chloride | 453 | 99 |
| Memantine Hcl | Memantine Hcl | 437 | 67 |
| Lisinopril | Lisinopril | 428 | 86 |
| Sertraline Hcl | Sertraline Hcl | 423 | 60 |
| Januvia | Sitagliptin Phosphate | 413 | 35 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 408 | 76 |
| Metformin Hcl | Metformin Hcl | 404 | 70 |
| Hydrochlorothiazide | Hydrochlorothiazide | 389 | 106 |
| Donepezil Hcl | Donepezil Hcl | 388 | 58 |
| Omeprazole | Omeprazole | 342 | 63 |
| Carvedilol | Carvedilol | 325 | 61 |
| Metoprolol Succinate | Metoprolol Succinate | 314 | 58 |
| Pravastatin Sodium | Pravastatin Sodium | 298 | 50 |
| Levetiracetam | Levetiracetam | 279 | 30 |
| Valsartan | Valsartan | 275 | 48 |
| Escitalopram Oxalate | Escitalopram Oxalate | 261 | 54 |
| Myrbetriq | Mirabegron | 248 | 21 |
| Torsemide | Torsemide | 247 | 38 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 226 | 49 |
| Farxiga | Dapagliflozin Propanediol | 223 | 27 |
| Finasteride | Finasteride | 223 | 35 |
| Jardiance | Empagliflozin | 215 | 22 |
| Metformin Hcl Er | Metformin Hcl | 187 | 51 |
| Glipizide | Glipizide | 183 | 38 |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 179 | 36 |
| Montelukast Sodium | Montelukast Sodium | 175 | 34 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 175 | 40 |
| Famotidine | Famotidine | 170 | 26 |
| Tramadol Hcl | Tramadol Hcl | 152 | 60 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 149 | 30 |
| Allopurinol | Allopurinol | 147 | 39 |
| Risperidone | Risperidone | 140 | 20 |
| Ropinirole Hcl | Ropinirole Hcl | 138 | 23 |
| Meloxicam | Meloxicam | 136 | 35 |
| Fluoxetine Hcl | Fluoxetine Hcl | 133 | 24 |
| Quetiapine Fumarate | Quetiapine Fumarate | 126 | 18 |
| Tradjenta | Linagliptin | 122 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 117 | 22 |
| Alprazolam | Alprazolam | 116 | 28 |
| Hydralazine Hcl | Hydralazine Hcl | 112 | 28 |
| Pregabalin | Pregabalin | 109 | 28 |
| Lorazepam | Lorazepam | 108 | 24 |
| Nifedipine Er | Nifedipine | 108 | 21 |
| Baclofen | Baclofen | 105 | 16 |
| Bupropion Xl | Bupropion Hcl | 104 | 27 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 103 | 35 |
| Fluticasone Propionate | Fluticasone Propionate | 102 | 32 |
| Cephalexin | Cephalexin | 100 | 59 |
| Ezetimibe | Ezetimibe | 100 | 29 |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 100 | 37 |
| Nebivolol Hcl | Nebivolol Hcl | 99 | 25 |
| Ondansetron Hcl | Ondansetron Hcl | 98 | 40 |
| Amitriptyline Hcl | Amitriptyline Hcl | 96 | 23 |
| Sucralfate | Sucralfate | 96 | 19 |
| Labetalol Hcl | Labetalol Hcl | 95 | 12 |
| Olanzapine | Olanzapine | 94 | 17 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 92 | 13 |
| Spironolactone | Spironolactone | 92 | 16 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 90 | 14 |
| Buspirone Hcl | Buspirone Hcl | 89 | 19 |
| Divalproex Sodium | Divalproex Sodium | 89 | 16 |
| Irbesartan | Irbesartan | 89 | 18 |
| Atenolol | Atenolol | 88 | 13 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 88 | 11 |
| Paroxetine Hcl | Paroxetine Hcl | 87 | 16 |
| Linzess | Linaclotide | 86 | 20 |
| Oxybutynin Chloride | Oxybutynin Chloride | 86 | 13 |
| Mounjaro | Tirzepatide | 85 | 18 |
| Rivastigmine | Rivastigmine Tartrate | 79 | 12 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 78 | 57 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 78 | 18 |
| Pentoxifylline | Pentoxifylline | 77 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 76 | 20 |
| Nystatin | Nystatin | 75 | 24 |
| Azithromycin | Azithromycin | 73 | 43 |
| Megestrol Acetate | Megestrol Acetate | 72 | 29 |
| Pioglitazone Hcl | Pioglitazone Hcl | 71 | 19 |
| Entresto | Sacubitril/Valsartan | 70 | suppressed |
| Methylprednisolone | Methylprednisolone | 70 | 57 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 69 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 65 | 18 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 65 | 12 |
| Clonazepam | Clonazepam | 65 | 19 |
| Clonidine Hcl | Clonidine Hcl | 65 | 22 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 64 | 11 |
| Amoxicillin | Amoxicillin | 63 | 49 |
| Humalog Kwikpen U-100 | Insulin Lispro | 63 | 13 |
| Synthroid | Levothyroxine Sodium | 62 | 16 |
| Prednisone | Prednisone | 61 | 28 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 59 | 29 |
| Latanoprost | Latanoprost | 59 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 58 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 58 | 11 |
| Ranolazine Er | Ranolazine | 58 | suppressed |
| Novolog Flexpen | Insulin Aspart | 55 | 16 |
| Xarelto | Rivaroxaban | 55 | suppressed |
| Lactulose | Lactulose | 54 | 14 |
| Tizanidine Hcl | Tizanidine Hcl | 54 | 15 |
| Albuterol Sulfate | Albuterol Sulfate | 51 | 15 |
| Ondansetron Odt | Ondansetron | 51 | 18 |
| Ipratropium Bromide | Ipratropium Bromide | 50 | 13 |
| Simvastatin | Simvastatin | 50 | 16 |
| Lansoprazole | Lansoprazole | 49 | suppressed |
| Mupirocin | Mupirocin | 49 | 28 |
| Primidone | Primidone | 46 | suppressed |
| Aripiprazole | Aripiprazole | 45 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 45 | 11 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 43 | suppressed |
| Celecoxib | Celecoxib | 43 | 11 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 43 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 43 | 14 |
| Divalproex Sodium Er | Divalproex Sodium | 42 | suppressed |
| Rayos | Prednisone | 42 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 41 | 13 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 40 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 40 | 16 |
| Sevelamer Carbonate | Sevelamer Carbonate | 39 | suppressed |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 38 | 19 |
| Lamotrigine | Lamotrigine | 38 | suppressed |
| Anastrozole | Anastrozole | 36 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 36 | suppressed |
| Nitroglycerin | Nitroglycerin | 35 | 13 |
| Dapagliflozin | Dapagliflozin Propanediol | 34 | 12 |
| Fluconazole | Fluconazole | 34 | 27 |
| Levofloxacin | Levofloxacin | 34 | 23 |
| Meclizine Hcl | Meclizine Hcl | 34 | 15 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 34 | 19 |
| Ozempic | Semaglutide | 33 | suppressed |
| Valproic Acid | Valproic Acid (As Sodium Salt) | 33 | suppressed |
| Candesartan Cilexetil | Candesartan Cilexetil | 32 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 32 | suppressed |
| Estradiol | Estradiol | 32 | suppressed |
| Rivastigmine | Rivastigmine | 32 | suppressed |
| Hydrocortisone | Hydrocortisone | 31 | 15 |
| Cholestyramine | Cholestyramine (With Sugar) | 30 | 11 |
| Doxycycline Hyclate | Doxycycline Hyclate | 30 | 24 |
| Trintellix | Vortioxetine Hydrobromide | 30 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 29 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 29 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 28 | suppressed |
| Clonidine | Clonidine | 28 | suppressed |
| Folic Acid | Folic Acid | 28 | suppressed |
| Letrozole | Letrozole | 28 | suppressed |
| Lidocaine Hcl | Lidocaine Hcl | 28 | 24 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 28 | suppressed |
| Lumigan | Bimatoprost | 28 | suppressed |
| Temazepam | Temazepam | 28 | suppressed |
| Creon | Lipase/Protease/Amylase | 27 | suppressed |
| Diazepam | Diazepam | 27 | 11 |
| Ketoconazole | Ketoconazole | 27 | 14 |
| Promethazine Hcl | Promethazine Hcl | 27 | 16 |
| Calcitriol | Calcitriol | 26 | suppressed |
| Lovastatin | Lovastatin | 26 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 26 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 26 | suppressed |
| Budesonide | Budesonide | 25 | suppressed |
| Gemtesa | Vibegron | 25 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 25 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 25 | suppressed |
| Metolazone | Metolazone | 25 | suppressed |
| Rabeprazole Sodium | Rabeprazole Sodium | 25 | suppressed |
| Rexulti | Brexpiprazole | 25 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 25 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 23 | 18 |
| Azelastine Hcl | Azelastine Hcl | 23 | suppressed |
| Metronidazole | Metronidazole | 23 | 14 |
| Carbamazepine | Carbamazepine | 22 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 22 | suppressed |
| Haloperidol | Haloperidol | 22 | suppressed |
| Lidocaine | Lidocaine | 22 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 21 | suppressed |
| Invega Sustenna | Paliperidone Palmitate | 21 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 21 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 21 | suppressed |
| Acetazolamide | Acetazolamide | 20 | suppressed |
| Bumetanide | Bumetanide | 20 | suppressed |
| Lubiprostone | Lubiprostone | 20 | suppressed |
| Erythromycin | Erythromycin Base | 19 | suppressed |
| Klor-Con 10 | Potassium Chloride | 19 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 19 | suppressed |
| Zonisamide | Zonisamide | 19 | suppressed |
| Namzaric | Memantine Hcl/Donepezil Hcl | 18 | suppressed |
| Timolol Maleate | Timolol Maleate | 18 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 18 | suppressed |
| Cefdinir | Cefdinir | 17 | 11 |
| Glimepiride | Glimepiride | 17 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 17 | suppressed |
| Novolog | Insulin Aspart | 17 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 17 | suppressed |
| Vraylar | Cariprazine Hcl | 17 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 16 | suppressed |
| Clorazepate Dipotassium | Clorazepate Dipotassium | 16 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 16 | 12 |
| Diltiazem 12hr Er | Diltiazem Hcl | 16 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 16 | suppressed |
| Hydroxyurea | Hydroxyurea | 16 | suppressed |
| Minoxidil | Minoxidil | 16 | suppressed |
| Rybelsus | Semaglutide | 16 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 16 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 15 | suppressed |
| Ketorolac Tromethamine | Ketorolac Tromethamine | 15 | suppressed |
| Prasugrel Hcl | Prasugrel Hcl | 15 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 15 | suppressed |
| Cholestyramine Light | Cholestyramine | 14 | suppressed |
| Dorzolamide-Timolol | Dorzolamide Hcl/Timolol Maleat | 14 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 14 | suppressed |
| Ilevro | Nepafenac | 14 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Nystop | Nystatin | 14 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 14 | suppressed |
| Sotalol | Sotalol Hcl | 14 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 14 | suppressed |
| Verapamil Er | Verapamil Hcl | 14 | suppressed |
| Vilazodone Hcl | Vilazodone Hcl | 14 | suppressed |
| Cilostazol | Cilostazol | 13 | suppressed |
| Colesevelam Hcl | Colesevelam Hcl | 13 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 13 | suppressed |
| Ibuprofen | Ibuprofen | 13 | suppressed |
| Trulicity | Dulaglutide | 13 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 12 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 12 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 12 | suppressed |
| Chlorpromazine Hcl | Chlorpromazine Hcl | 12 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 12 | suppressed |
| Humalog | Insulin Lispro | 12 | suppressed |
| Insulin Aspart Flexpen | Insulin Aspart | 12 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 12 | suppressed |
| Methimazole | Methimazole | 12 | suppressed |
| Olanzapine Odt | Olanzapine | 12 | suppressed |
| Theo-24 | Theophylline Anhydrous | 12 | suppressed |
| Tresiba | Insulin Degludec | 12 | suppressed |
| Bicalutamide | Bicalutamide | 11 | suppressed |
| Carteolol Hcl | Carteolol Hcl | 11 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 11 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 11 | suppressed |
| Levemir Flexpen | Insulin Detemir | 11 | suppressed |
| Mirabegron Er | Mirabegron | 11 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $976.90 · 44 records | Amgen Inc. | AIRSUPRA, AREXVY, Auvelity, CAPLYTA, CONTRAVE, Cologuard Collection Kit, Dexcom G6 Transmitter, ELIQUIS, EVENITY, FARXIGA, JARDIANCE, LEQVIO, MOUNJARO, Ozempic, QULIPTA, REXULTI, SHINGRIX, SKYCLARYS, TRINTELLIX, UBRELVY, XIFAXAN, ZEPBOUND | 20 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error